Parkinson's Disease
Conditions
Brief summary
The purpose of the study is to determine if the pharmacokinetic profile of V1512 is similar or better than existing medications for the treatment of Parkinson's Disease
Detailed description
The pharmacokinetics of V1512 effervescent tablet has been evaluated in healthy volunteers, however not fully in PD patients. This study aims to evaluate the PK profiles in PD patients of different dosing schedules of V1512 effervescent tablet compared to the profiles after standard L-dopa/carbidopa (Sinemet) over the course of the day. Two dosing schedules have been chosen to evaluate a possible relation between dosing interval and 'ON' time, with and without associated dyskinesia. Similar dosing schedules with the comparator Sinemet are commonly employed in the treatment of fluctuating PD patients. Patients assigned to cohort 3 will also take a dose of entacapone concomitantly with each dose of V1512 or Sinemet, thereby allowing the kinetics and dynamics of.V1512 and Sinemet to be compared in the presence of COMT inhibition. Safety and tolerability of the dosing regimens in patients will also be assessed further in this double-blind study
Interventions
DRUGV1512
6 doses of IMP at 2-hourly intervals
DRUGV1512 and Entacapone
4 doses of IMP and Entacapone at 3-hourly intervals
Sponsors
Cita NeuroPharmaceuticals
Syneos Health
Vernalis (R&D) Ltd
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female, \>30 years of age of any race; 2. A Body Mass Index between 18.5 and 29.9 kg/m2 (inclusive); 3. Clinical diagnosis according to the Brain Bank diagnostic criteria of idiopathic Parkinson's Disease (2 of 3 cardinal symptoms - bradykinesia, rigidity, tremor -must be present, with a positive response to L-dopa); 4. Presence of fluctuations in motor performance with \>2 hours inclusive of daytime OFF episodes (not applicable for cohort 1 patients); 5. At least 1 hour delay to ON time with afternoon doses; 6. Discontinued use of COMT inhibitors (cathecol-o-methyl transferase) for at least 2 weeks prior to study entry (not applicable for cohort 3 patients); 7. Stable doses of dopamine agonists or selegiline for at least 2 weeks before entry into the study; 8. Stable comorbidity for 4 weeks; 9. Female patients must be of non-childbearing potential (post-menopausal or physically incapable of childbearing); 10. Willing and able to give informed consent according to national legal requirements prior to initiation of any study-related procedures
Exclusion criteria
1. Clinically relevant abnormal vital sign values or safety laboratory data. 2. Patients who smoke and are unable to refrain from smoking during the in-clinic period 3. Diagnosis of atypical parkinsonism; 4. A history and/or the presence of gastro-intestinal disorders (or surgery) that could interfere with absorption of the test medication; 5. A history of intolerance or clinically relevant allergy to L-dopa and/or carbidopa taken in any formulation or combination; 6. A history of intolerance or clinically relevant allergy to entacapone or any ingredients of Comtan (cohort 3 patients only) 7. Any other condition which, in the opinion of the Investigator, would interfere with optimal participation in the study e.g. inability to complete patient diary; 8. Participation in any clinical study or receiving treatment with another investigational drug within 30 days or 5 half lives (whichever is longer) before the screening visit; 9. Blood donation within 3 months before study participation; 10. History of neuroleptic malignant syndrome (NMS) or NMS-like syndromes, or non-traumatic rhabdomyolysis; 11. Patients taking non-selective MAO inhibitors; 12. Patients with a history of, or clinical indication of, narrow angle glaucoma; 13. Patients with a history of, or clinical indication of, malignant melanoma; 14. Patients with a history of, or clinical indication of, depression or psychosis; 15. Patients taking iron containing medications (ferrous sulphate, ferrous gluconate)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to characterise the plasma concentrations of L-dopa after repeated doses of V1512 in fluctuating PD patients compared to standard L-dopa/carbidopa (Sinemet) over the course of the day | 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| correlate plasma concentrations with response to therapy; | 4 weeks |
| further characterise the safety and tolerability profile for each treatment | 4 weeks |
Countries
Italy
Outcome results
None listed